Literature DB >> 12208966

Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein.

Shi-Hua Xiang1, Peter D Kwong, Rishi Gupta, Carlo D Rizzuto, David J Casper, Richard Wyatt, Liping Wang, Wayne A Hendrickson, Michael L Doyle, Joseph Sodroski.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) gp120 exterior envelope glycoprotein is conformationally flexible. Upon binding to the host cell receptor CD4, gp120 assumes a conformation that is recognized by the second receptor, CCR5 and/or CXCR4, and by the CD4-induced (CD4i) antibodies. Guided by the X-ray crystal structure of a gp120-CD4-CD4i antibody complex, we introduced changes into gp120 that were designed to stabilize or disrupt this conformation. One mutant, 375 S/W, in which the tryptophan indole group is predicted to occupy the Phe 43 cavity in the gp120 interior, apparently favors a gp120 conformation closer to that of the CD4-bound state. The 375 S/W mutant was recognized as well as or better than wild-type gp120 by CD4 and CD4i antibodies, and the large decrease in entropy observed when wild-type gp120 bound CD4 was reduced for the 375 S/W mutant. The recognition of the 375 S/W mutant by CD4BS antibodies, which are directed against the CD4-binding region of gp120, was markedly reduced compared with that of the wild-type gp120. Compared with the wild-type virus, viruses with the 375 S/W envelope glycoproteins were resistant to neutralization by IgG1b12, a CD4BS antibody, were slightly more sensitive to soluble CD4 neutralization and were neutralized more efficiently by the 2G12 antibody. Another mutant, 423 I/P, in which the gp120 bridging sheet was disrupted, did not bind CD4, CCR5, or CD4i antibodies, even though recognition by CD4BS antibodies was efficient. These results indicate that CD4BS antibodies recognize conformations of gp120 different from that recognized by CD4 and CD4i antibodies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12208966      PMCID: PMC136507          DOI: 10.1128/jvi.76.19.9888-9899.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  101 in total

1.  Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies.

Authors:  J P Moore; F E McCutchan; S W Poon; J Mascola; J Liu; Y Cao; D D Ho
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

2.  Effects of cavity-creating mutations on conformational stability and structure of the dimeric 4-alpha-helical protein ROP: thermal unfolding studies.

Authors:  C Steif; H J Hinz; G Cesareni
Journal:  Proteins       Date:  1995-09

3.  Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.

Authors:  R Wyatt; J Moore; M Accola; E Desjardin; J Robinson; J Sodroski
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

4.  A single amino acid substitution can restore the solubility of aggregated colicin A mutants in Escherichia coli.

Authors:  J Izard; M W Parker; M Chartier; D Duché; D Baty
Journal:  Protein Eng       Date:  1994-12

5.  Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.

Authors:  N Sullivan; Y Sun; J Li; W Hofmann; J Sodroski
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

6.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.

Authors:  A Trkola; M Purtscher; T Muster; C Ballaun; A Buchacher; N Sullivan; K Srinivasan; J Sodroski; J P Moore; H Katinger
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

7.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.

Authors:  P D Kwong; R Wyatt; J Robinson; R W Sweet; J Sodroski; W A Hendrickson
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

8.  Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.

Authors:  J P Moore; Y Cao; L Qing; Q J Sattentau; J Pyati; R Koduri; J Robinson; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

9.  The human immunodeficiency virus gp120 binding site on CD4: delineation by quantitative equilibrium and kinetic binding studies of mutants in conjunction with a high-resolution CD4 atomic structure.

Authors:  U Moebius; L K Clayton; S Abraham; S C Harrison; E L Reinherz
Journal:  J Exp Med       Date:  1992-08-01       Impact factor: 14.307

10.  Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer.

Authors:  Q J Sattentau; J P Moore
Journal:  J Exp Med       Date:  1995-07-01       Impact factor: 14.307

View more
  115 in total

1.  CD4 binding site antibodies inhibit human immunodeficiency virus gp120 envelope glycoprotein interaction with CCR5.

Authors:  Aarti Raja; Miro Venturi; Peter Kwong; Joseph Sodroski
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043.

Authors:  Nannan Zhou; Beata Nowicka-Sans; Sharon Zhang; Li Fan; Jie Fang; Hua Fang; Yi-Fei Gong; Betsy Eggers; David R Langley; Tao Wang; John Kadow; Dennis Grasela; George J Hanna; Louis Alexander; Richard Colonno; Mark Krystal; Pin-Fang Lin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

3.  Range of CD4-Bound Conformations of HIV-1 gp120, as Defined Using Conditional CD4-Induced Antibodies.

Authors:  Gilad Kaplan; Anna Roitburd-Berman; George K Lewis; Jonathan M Gershoni
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

Review 4.  HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth.

Authors:  Priyamvada Acharya; Sabrina Lusvarghi; Carole A Bewley; Peter D Kwong
Journal:  Expert Opin Ther Targets       Date:  2015-02-27       Impact factor: 6.902

5.  Entropy calculation of HIV-1 Env gp120, its receptor CD4, and their complex: an analysis of configurational entropy changes upon complexation.

Authors:  Shang-Te D Hsu; Christine Peter; Wilfred F van Gunsteren; Alexandre M J J Bonvin
Journal:  Biophys J       Date:  2004-10-15       Impact factor: 4.033

6.  Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions.

Authors:  Qi Guo; Hsu-Tso Ho; Ira Dicker; Li Fan; Nannan Zhou; Jacques Friborg; Tao Wang; Brian V McAuliffe; Hwei-Gene Heidi Wang; Ronald E Rose; Hua Fang; Helen T Scarnati; David R Langley; Nicholas A Meanwell; Ralph Abraham; Richard J Colonno; Pin-Fang Lin
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 7.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

8.  Escherichia coli surface display of single-chain antibody VRC01 against HIV-1 infection.

Authors:  Lin-Xu Wang; Michael Mellon; Dane Bowder; Meghan Quinn; Danielle Shea; Charles Wood; Shi-Hua Xiang
Journal:  Virology       Date:  2014-12-05       Impact factor: 3.616

9.  The highly conserved layer-3 component of the HIV-1 gp120 inner domain is critical for CD4-required conformational transitions.

Authors:  Anik Désormeaux; Mathieu Coutu; Halima Medjahed; Beatriz Pacheco; Alon Herschhorn; Christopher Gu; Shi-Hua Xiang; Youdong Mao; Joseph Sodroski; Andrés Finzi
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

10.  Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates.

Authors:  Iyadh Douagi; Mattias N E Forsell; Christopher Sundling; Sijy O'Dell; Yu Feng; Pia Dosenovic; Yuxing Li; Robert Seder; Karin Loré; John R Mascola; Richard T Wyatt; Gunilla B Karlsson Hedestam
Journal:  J Virol       Date:  2009-12-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.